Oct 20, 2022

Featuring a slide presentation and related discussion from Prof Sia Daneshmand, including the following topics:

• Continuous intravesical drug delivery for patients with muscle-invasive urothelial bladder cancer (MIBC) (0:00)
• Current role of checkpoint inhibitors alone or in combination with chemotherapy for urothelial bladder cancer (UBC) (9:26)
• Emerging data with novel agents and strategies for the management of UBC (14:52)
• Case: A man in his mid 70s with a history of high-grade T1 disease who is not a good candidate for cystectomy (18:57)
• Case: A man in his early 80s with high-grade T2 MIBC who is not a candidate for cystectomy or neoadjuvant chemotherapy (22:27)
• Case: A woman in her late 50s with completely resected UBC with a strong preference for bladder-sparing treatment (24:43)

CME information and select publications